PSNL insider trading

About Personalis, Inc.

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; and NeXT Dx, a tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. In addition, the company performs whole exome sequencing of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing on human samples for research projects, such as population sequencing initiatives. Its services are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies, and for clinical trials, as well as tests are used by physicians to detect residual or recurrent cancer in patients, monitor cancer response to therapy, and uncover insights for therapy selection. The company's customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company has strategic collaboration with Tempus AI, Inc. to bring ultra-sensitive cancer recurrence testing to colorectal cancer patients. Personalis, Inc. was incorporated in 2011 and is headquartered in Fremont, California.

Company website: www.personalis.com

PSNL insider activity at a glance

Latest PSNL Form 4 filings

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

Top insiders trading PSNL

Politicians who have traded PSNL

Frequently asked

How many insider trades does FilingIQ track for PSNL?

FilingIQ tracks 290 Form 4 insider transactions for PSNL (Personalis, Inc.), covering filings from Jun 24, 2019 onwards. 24 of those were filed in the last 90 days.

Are PSNL insiders net buyers or net sellers?

Across the full Form 4 history for PSNL, 23 transactions (8%) were open-market purchases and 149 (51%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does PSNL insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is PSNL in?

Personalis, Inc. (PSNL) is classified in the Healthcare sector, specifically Diagnostics & Research, with a current market capitalisation of $764.61M.